Patents Issued in January 30, 2024
  • Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections
    Patent number: 11883388
    Abstract: The present invention relates to a method of reducing or preventing the symptoms associated with the common cold. The method comprises administering to a subject an effective amount of a pharmaceutical composition before presenting with at least one symptom of the common cold. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, salts thereof, and combinations thereof.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 30, 2024
    Assignee: SEN-JAM Pharmaceutical Inc.
    Inventors: Jacqueline M. Iversen, Thomas A. Dahl
  • Formulations of 2-(4-chlorophenyl)-N-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
    Patent number: 11883389
    Abstract: Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: January 30, 2024
    Assignee: Celgene Corporation
    Inventors: Ho-Wah Hui, Yu Pu
  • Ophthalmic composition
    Patent number: 11883390
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: January 30, 2024
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
    Patent number: 11883391
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 30, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: James Campbell, Israel Charo, Thomas Schall, Rajinder Singh, Yibin Zeng, Penglie Zhang
  • Pharmaceutical composition for nasal delivery
    Patent number: 11883392
    Abstract: According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: January 30, 2024
    Assignee: OREXO AB
    Inventors: Jonas Sävmarker, Robert Rönn, Andreas Fischer
  • Compounds and methods for the targeted degradation of androgen receptor
    Patent number: 11883393
    Abstract: This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: January 30, 2024
    Assignee: Arvinas Operations, Inc.
    Inventors: Lawrence B. Snyder, Hanqing Dong
  • Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
    Patent number: 11883394
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: January 30, 2024
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor
    Patent number: 11883395
    Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: January 30, 2024
    Assignee: The University of Vermont and State Agricultural College
    Inventors: Vikas Anathy, Nicolas Chamberlain, Amit Kumar
  • Methods of treating kidney conditions using modified forms of trimetazidine
    Patent number: 11883396
    Abstract: The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: January 30, 2024
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Paul Chamberlin
  • Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
    Patent number: 11883397
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: January 30, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Manoj C. Desai, Mingzhe Ji, Haolun Jin, Hyung-Jung Pyun, Teresa Alejandra Trejo Martin
  • Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
    Patent number: 11883398
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: January 30, 2024
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Bromocriptine formulations
    Patent number: 11883399
    Abstract: The present disclosure describes pharmaceutical formulations of bromocriptine and method of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: January 30, 2024
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Treatment of portal hypertension and cirrhosis
    Patent number: 11883400
    Abstract: Methods and formulations are provided for the treatment and prevention of portal hypertension.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: January 30, 2024
    Assignee: Noorik Biopharmaceuticals AG
    Inventor: Iker Navarro
  • Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
    Patent number: 11883401
    Abstract: The present disclosure provides compositions and methods for the treatment of pathogen-induced and/or chemical-induced lung injury, for regenerating lung epithelial cells following lung injury, for treating cancer, and for sensitizing a subject suffering from cancer to a chemotherapeutic agent.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: January 30, 2024
    Assignee: Duke University
    Inventors: Ann Marie Pendergast, Aaditya Khatri
  • Crystalline forms of a quinazoline compound and its hydrochloride salts
    Patent number: 11883402
    Abstract: This patent document relates to the crystalline forms of a quinazoline compound and the hydrochloride salts thereof. More particularly, this patent document relates to a preparation method of the crystalline forms of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one and its hydrochloride salts.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: January 30, 2024
    Assignees: Hanmi Pharmaceutical Co., Ltd., Spectrum Pharmaceuticals, Inc.
    Inventors: Jong Ouk Baek, Hee Cheol Kim, Tae Hee Ha, Kweehyun Suh, Guru Reddy
  • Pharmaceutical compositions comprising Afatinib
    Patent number: 11883403
    Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: January 30, 2024
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Rajesh Khanna, Neeraj Kumar, Vijay Kumar Sharma, Ankit Gaur, Dhiraj Khattar
  • Preparation and composition for treatment of malignant tumors
    Patent number: 11883404
    Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 30, 2024
    Assignee: Taiho Pharmaceuticals Co., Ltd.
    Inventors: Akihiro Miura, Hiroshi Sootome, Junya Iwasaki
  • Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
    Patent number: 11883405
    Abstract: The present invention relates to a pharmaceutical product comprising a combination of methotrexate and novobiocin, or any pharmaceutically acceptable salts of said compounds, and a pharmaceutical composition comprising (i) a therapeutic amount of methotrexate or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent, (ii) a non-therapeutic amount of novobiocin or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent. The invention further relates to a use of the pharmaceutical product and composition in therapy, such as prevention, progression prophylaxis and/or treatment of autoimmune diseases.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: January 30, 2024
    Assignee: AMPLIO PHARMA AB
    Inventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
  • Method for producing alginic acid-folic acid conjugate, alginic acid-folic acid conjugate produced thereby and pharmaceutical composition containing the same
    Patent number: 11883406
    Abstract: The present invention relates to a method for producing an alginic acid-folic acid conjugate, an alginic acid-folic acid conjugate produced thereby, and a pharmaceutical composition containing the same. According to the method of producing an alginic acid-folic acid conjugate using a carboxy-protecting group and a leaving group, the hydroxyl group of alginic acid forms an ester group with the carboxyl group of folic acid. Thus, the alginic acid-folic acid conjugate may clearly distinguish cancer cells from normal tissue by more effectively targeting cancer cells than a conventional alginic acid-conjugated folic acid in which the amine group of folic acid is covalently bonded to the carboxyl group of alginic acid. Accordingly, the alginic acid-folic acid conjugate may be effectively used for precise diagnosis and efficient surgical resection of cancer lesions.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: January 30, 2024
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Kang Won Lee, Sa Ra Lee
  • Medicament for the treatment of chronic cough
    Patent number: 11883407
    Abstract: Provided is a pharmaceutical composition for treating chronic cough, which has substantially no side effects of taste disturbance. A pharmaceutical composition for treating chronic cough, comprising a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: January 30, 2024
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Ryuta Tamano, Erika Kasai, Sayaka Miyazaki, Katsue Magari
  • Reboxetine to treat narcolepsy
    Patent number: 11883408
    Abstract: Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: January 30, 2024
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Protection of cells from degeneration and treatment of geographic atrophy
    Patent number: 11883409
    Abstract: Therapeutic uses P2X7 inhibition and inhibition of IRAK1 and/or IRAK4, methods protecting a cell, and screening methods for identifying inhibitors are described herein.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: January 30, 2024
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Preventative and therapeutic agents for sarcopenia
    Patent number: 11883410
    Abstract: This invention relates to a preventive and/or therapeutic agent for sarcopenia, comprising a prostaglandin D2 production inhibitor as an active ingredient.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: January 30, 2024
    Assignees: National University Corporation Tokyo University of Agriculture and Technolgy, Taiho Pharmaceutical Co., Ltd.
    Inventors: Masaki Inada, Daisuke Kajiwara
  • Use of compound aprepitant in preparation of drug for preventing or treating African swine fever (ASF)
    Patent number: 11883411
    Abstract: The present disclosure belongs to the technical field of African swine fever (ASF) treatment, in particular to use of a compound aprepitant in prevention or treatment of the ASF. In the present disclosure, it is found that the compound aprepitant can significantly inhibit replication of an African swine fever virus (ASFV); in addition, it is found that the aprepitant inhibits transcription and protein expression of D1133L, and reduces transcription and protein expression levels of p30 and p72, preventing virus invasion on host cells. Therefore, the compound aprepitant can be used to inhibit early and late infection of the ASFV. Accordingly, the compound aprepitant can be used to prevent or treat the ASF.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: January 30, 2024
    Assignee: LANZHOU VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Keshan Zhang, Haixue Zheng, Huimei Cui, Bo Yang, Hong Tian, Zixiang Zhu, Tao Feng, Fan Yang, Weijun Cao, Xusheng Ma, Yi Ru, Jianhong Guo, Xiangtao Liu
  • Treatment for cellulitis and pre-operative treatment
    Patent number: 11883412
    Abstract: A composition for treatment of cellulitis is provided that includes by weight: about 85% transdermal cream; about 5% Cephalexin or Clindamycin; about 5% Ketoprofen; and about 5% Lidocaine. The composition has a density of about 1 gram per milliliter.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: January 30, 2024
    Assignees: Multimode Medical Holdings Inc.
    Inventors: Patrick Musitano, Paul Zalzal
  • Inhibition of thymine DNA glycosylase in the treatment of cancer
    Patent number: 11883413
    Abstract: The invention provides compositions, kits, and methods for inducing growth arrest, differentiation, or senescence of cancer cells that express thymine DNA glycosylase, and treating the cancer accordingly. The methods comprise inhibiting expression or biologic activity of thymine DNA glycosylase in cancer cells. Inhibition of thymine DNA glycosylase in cancer cells may induce the cells to revert to a healthy, non-cancerous phenotype and/or may induce the cells to senesce. Cancer cells include melanoma, lung, prostate, pancreatic, ovarian, brain, colon, recto-sigmoid colon, and breast cancer cells.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: January 30, 2024
    Inventors: Alfonso Bellacosa, Rossella Tricarico, Tim Yen, Vikram Bhattacharjee, Pietro Mancuso, Lionel Larue, Irwin Davidson
  • Methods of reducing mammographic breast density and/or breast cancer risk
    Patent number: 11883414
    Abstract: The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-menopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: January 30, 2024
    Assignee: Havah Therapeutics Pty Ltd.
    Inventor: Stephen Nigel Birrell
  • High concentration formulation
    Patent number: 11883415
    Abstract: The present disclosure provides high concentration formulations of cortexolone-17?-propionate suitable for treating alopecia.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: January 30, 2024
    Assignee: Cassiopea S.P.A.
    Inventor: Luigi Maria Longo
  • Methods and compositions for the treatment of IL13Ra2—overexpressing cancer
    Patent number: 11883416
    Abstract: The invention relates to methods and compositions for treatment of IL13R?2-overexpressing cancer, wherein the treatment comprises administering a protein tyrosine phosphatase-1B (PTP1B) inhibitor.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: January 30, 2024
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)
    Inventors: José Ignacio Casal Álvarez, Rubén Álvaro Bartolomé Conde
  • Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
    Patent number: 11883417
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: January 30, 2024
    Assignee: The University of Chicago
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • Compound TSYI-ZAC for inhibiting dengue virus infection and medicinal use thereof
    Patent number: 11883418
    Abstract: A compound TSYI-ZAC (Zhankuic acid C) used in a method for treating dengue virus infection, in which a pharmaceutical composition can further comprise a 4,7-dimethoxy-5-methyl-1,3-benzodioxole compound capable of inhibiting dengue virus infection by down-regulating an expression of IL-6 and IL-8, and increasing a secretion of IFN-?.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: January 30, 2024
    Assignee: SYI BIOTECHNOLOGY CO., LTD.
    Inventors: Chia-Chang Chen, Guey-Chuen Perng, Hsiu-Man Lien, Yi-Ju Chen
  • DNA polymerase gamma inhibitor and uses thereof
    Patent number: 11883419
    Abstract: Pol ? protein inhibitor compounds are useful for selectively inhibiting the growth of MLH1 mutant/deficient tumor or cancer cells due to a synthetic lethal relationship between MLH1 and Pol ?. The compounds were shown to directly interact with Pol ? and inhibit its biological function and cause cancer cell death and an inhibition of tumor or cancer cell growth in multiple assays.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 30, 2024
    Assignees: ACIBADEM MEHMET ALI AYDINLAR UNIVERSITESI, SABANCI UNIVERSITESI, KOC UNIVERSITESI
    Inventors: Meltem Muftuoglu, Batu Erman, Burak Erman
  • Sting agonists for treating bladder cancer and solid tumors
    Patent number: 11883420
    Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: January 30, 2024
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: Brian F. McGuinness, Grant Gallagher, Michael S. McQueney, Rukiye Nazan Eraslan, Gary Schieven, Jason Trama, Axel Metzger, David J. Diller, David E. Kaelin
  • Functionalized saccharides as anti-inflammatory agents
    Patent number: 11883421
    Abstract: The present invention relates to functionalized saccharides anti-inflammatory agents which acts upon inflammatory mechanisms in mammals, in particular anti-inflammatory agents which act upon the expression of at least one cytokine by suppressing or inhibiting the expression of the at least one cytokine wherein said cytokine is selected from the group consisting of pro-inflammatory cytokines, anti-inflammatory cytokines and chemokines.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 30, 2024
    Assignee: HUVEPHARMA
    Inventors: Spas Petkov, Veerle Hautekiet
  • Glycan therapeutic compositions and related methods thereof
    Patent number: 11883422
    Abstract: Preparations of glycan therapeutics, pharmaceutical compositions, dietary supplements and medical foods thereof are provided, and methods of using said glycan therapeutics, e.g. in cancer therapy.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: January 30, 2024
    Assignee: DSM Nutritional Products, LLC
    Inventors: Geoffrey A. von Maltzahn, Yvonne J. Yamanaka, Jared Silverman, John Miles Milwid, Jacob Rosenblum Rubens, John M. Geremia
  • Nucleobase analogue derivatives and their applications
    Patent number: 11883423
    Abstract: Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: January 30, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhengrong Cui, Dharmika Lansakara-P.
  • Methods of making novel pharmaceutical compositions
    Patent number: 11883424
    Abstract: The present invention relates to compositions comprising complexes that are formed by polyinosinic-polycytidylic acid with a polyalkyleneimine, such as polyethyleneimine, that present uniform structural and functional features, as well as to methods for preparing the compositions that comply with regulatory requirements. The present invention additionally relates to use of said compositions as medicaments (in particular for treating cancer), alone or in combination with other therapeutic agents and/or in specific medical methods. Moreover, the administration of these compositions is associated to changes in the expression of specific genes, in cell responses, and/or in composition of immune cell populations that can be used as specific biomarkers and/or as additional target for medical treatment.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: January 30, 2024
    Assignee: Highlight Therapeutics, S.L.
    Inventors: Marisol Quintero Ortiz, Mercedes Pozuelo Rubio, Lourdes Planelles Carazo
  • Metformin compositions and methods for treatment of diabetes
    Patent number: 11883425
    Abstract: The invention provides compositions and methods to treat diabetes with improved formulations in which metformin is combined with at least three antioxidants that contain a stabilizing heteroatom adjacent to a saturated carbon and which help maintain a balance between antioxidant and pro-oxidant properties. The antioxidants include at least the combination of taurine, citrulline and methylcobalamin, and optionally include melatonin. The composition provides management of blood glucose levels comparable to metformin in the same dose without antioxidants, without the phenomenon of undermining metformin performance that is commonly observed in the presence of co-administered antioxidants.
    Type: Grant
    Filed: April 18, 2022
    Date of Patent: January 30, 2024
    Inventor: William H. Cross, III
  • Treatment for methamphetamine cardiovascular disease
    Patent number: 11883426
    Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, allicin, sugammadex, sulfanilamide, disulfiram, sulfonamide, sulfonates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: January 30, 2024
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher Kevil, Gopi K. Kolluru
  • Formulations for treating acid reflux comprising sodium alginate
    Patent number: 11883427
    Abstract: The disclosure provides for pharmaceutical compositions comprising an alginate salt, such as sodium alginate. The disclosure further provides for processes and methods for making pharmaceutical compositions. In yet a further aspect, the disclosure provides for methods of utilizing a pharmaceutical composition for treatment of acid reflux diseases. In another aspect, the disclosure provides for formulations suitable for oral use in dosage forms of capsules and dry powders.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: January 30, 2024
    Assignee: PHARAGEN LLC
    Inventor: Joseph Ryan Smolarz
  • Enteric aerobization therapy
    Patent number: 11883428
    Abstract: Agents, kits, and methods that utilize oxygenation to prevent and/or treat infections caused by anaerobic microorganisms are provided. The agents, kits, and methods according to several embodiments utilize oxygenation in the intestinal lumen to prevent and/or treat infections caused by anaerobic bacteria. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: January 30, 2024
    Assignee: LPOXY THERAPEUTICS, INC.
    Inventor: Larry D. Sutton
  • Therapeutic pooled blood apoptotic cell preparations and uses thereof
    Patent number: 11883429
    Abstract: Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: January 30, 2024
    Assignee: Enlivex Therapeutics RDO Ltd
    Inventors: Dror Mevorach, Shai Novik
  • CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
    Patent number: 11883430
    Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: January 30, 2024
    Assignee: MUSC Foundation for Research Development
    Inventors: Shikhar Mehrotra, Shilpak Chatterjee
  • T-cells modified to overexpress PHF19
    Patent number: 11883431
    Abstract: Provided is a mammalian T cell modified to express the Phf19 at a level that is higher than the level of Phf19 expressed by a T cell that has not been modified to express Phf19. Provided is a genetically-modified mammalian T cell comprising a genetic expression vector comprising (a) virally-, bacterially-, or both virally- and bacterially-derived genetic sequences and (b) a genetic sequence encoding Phf19, whereby the genetic sequence encoding Phf19 within the vector is expressed within the T cell. Pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells by epigenetic reprogramming are also provided.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: January 30, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Yun Ji, Luca Gattinoni
  • Chimeric antigen receptor system with adaptable receptor specificity
    Patent number: 11883432
    Abstract: The present disclosure provides chimeric antigen receptors (CARs), particularly CARs that have adaptable receptor specificity (arCARs). Also provided are polypeptides of the CARs and other related molecules, polynucleotides, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: January 30, 2024
    Assignee: CENTURY THERAPEUTICS, INC.
    Inventors: Jill Marinari Carton, Michael Francis Naso, Luis Ghira Borges, John Wheeler, Andrew Devaney
  • Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof
    Patent number: 11883433
    Abstract: Provided is an anti-mesothelin chimeric antigen receptor that specifically binds to mesothelin. The anti-mesothelin chimeric antigen receptor according to an aspect exhibits a specific binding ability for mesothelin, and thus, may be useful for preventing or treating cancer in which mesothelin is overexpressed.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: January 30, 2024
    Assignee: CELLENGENE INC.
    Inventors: Jae Hyung An, Na Kyung Han
  • Extracellular vesicles and methods of using
    Patent number: 11883434
    Abstract: The present disclosure relates to materials and methods for extracellular vesicle (e.g., exosome)-mediated delivery of cargo (e.g., endogenous and/or exogenous) to non-bovine mammalian (e.g., human) cells. For example, exosomes isolated from bovine milk for delivering cargo to non-bovine mammalian (e.g., human) cells are provided.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: January 30, 2024
    Assignee: NUtech Ventures
    Inventor: Janos Zempleni
  • Compositions and methods for treating a clinical condition through the use of hematopoietic stem cells
    Patent number: 11883435
    Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of a condition/disease associated with insufficient quantity and/or quality of hematopoietic stem cells (HSCs) and differentiated blood cells thereof. Embodiments include compositions and methods for treating the condition/disease, comprising the step of providing to a subject at least one therapeutically effective dose of a composition disclosed herein. Other embodiments include methods for generating and/or collecting hematopoietic stem cells from a subject.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: January 30, 2024
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Hal Edward Broxmeyer, Maegan Lynn Capitano, Scott Harrison Cooper, Qingchun Cai
  • Method of preparing hematopoietic stem and progenitor cells for transplantation
    Patent number: 11883436
    Abstract: Disclosed are methods of preparing hematopoietic stem cells and progenitor cells (HSPCs) for transplant into a subject and to methods of using the treated cells. More particularly, methods of the invention comprise treating HSPCs ex vivo with an effective amount of a GABBR1 agonist and administering the treated HSPCs to the subject.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: January 30, 2024
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Owen James Tamplin, Kostandin Pajcini
  • Xenograft soft tissue implants and methods of making
    Patent number: 11883437
    Abstract: The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as dermis, and to implants produced by such processes.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: January 30, 2024
    Assignee: Tutogen Medical GmbH
    Inventors: Arnd Wilhelmi, Silke Schreiner, Jake Michaelson, Steven Moore, Jennifer Faleris, Anne Reinlein